Administration of the GABA_A receptor antagonist picrotoxin into rat supramammillary nucleus induces c-Fos in reward-related brain structures. 

Rick Shin, Satoshi Ikemoto*

Abstract

Background: Picrotoxin blocks GABA_A receptors, whose activation typically inhibits neuronal firing activity. We recently found that rats learn to selectively self-administer picrotoxin or bicuculline, another GABA_A receptor antagonist, into the supramammillary nucleus (SuM), a posterior hypothalamic structure localized anterior to the ventral tegmental area. Other drugs such as nicotine or the excitatory amino acid AMPA are also self-administered into the SuM. The SuM appears to be functionally linked with the mesolimbic dopamine system and is closely connected with other brain structures that are implicated in motivational processes, including the prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus. Here, we hypothesized that these brain structures are activated by picrotoxin injections into the SuM.

Results: Picrotoxin administration into the SuM markedly facilitated locomotion and rearing. Further, it increased c-Fos expression in this region, suggesting blockade of tonic inhibition and thus the disinhibition of local neurons. This manipulation also increased c-Fos expression in structures including the ventral tegmental area, medial shell of the nucleus accumbens, medial prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus.

Conclusions: Picrotoxin administration into the SuM appears to disinhibit local neurons and recruits activation of brain structures associated with motivational processes, including the mesolimbic dopamine system, prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus. These regions may be involved in mediating positive motivational effects triggered by intra-SuM picrotoxin.

Background

Recent intracranial self-administration studies have helped to define key brain structures involved in positive motivational processes involved in approach-seeking [1]. One such structure is the supramammillary nucleus (SuM), located in the posterior hypothalamic area, just dorsal to the mammillary body and anterior to the ventral tegmental area (VTA). The SuM was initially implicated in reward-related processes by the finding that rats learn instrumental responses to obtain brief electrical stimulation in the vicinity of the SuM [2]. We recently found that rats readily learn to lever-press for infusions of GABA_A receptor antagonists, picrotoxin or bicuculline [3], the excitatory amino acid AMPA [4], or nicotine [5] into the SuM, suggesting that activation of supramammillary neurons recruits approach-related motivational processes [1].

We have also shown low systemic doses of dopamine receptor antagonists decrease rats’ self-administration of picrotoxin or AMPA into the SuM [3,4]. These findings suggest that motivational effects of supramammillary manipulations depend on intact dopamine transmission. In addition, AMPA administration into the SuM increases extracellular dopamine concentrations in the ventral striatum as measured by microdialysis [4]. This result suggests that activation of supramammillary...
neurons appears to recruit activation of the mesolimbic dopamine system.

Conversely, some manipulations that activate VTA dopamine neurons appear to activate supramammillary neurons. One manipulation that supports robust self-administration is the cholinergic receptor agonist carbachol into the posterior VTA [6], which increases extracellular dopamine in the ventral striatum [7], suggesting that this manipulation activates the mesolimbic dopamine system. The administration of carbachol into the posterior VTA was found to robustly increase the transcription factor c-Fos in the SuM [8]. SuM c-Fos counts were positively correlated with locomotor counts increased by carbachol administration into the VTA, suggesting that SuM neurons participate in motivational effects triggered by posterior VTA activation. These findings suggest that supramammillary neurons interact with the mesolimbic dopamine system.

Although the SuM appears to be functionally linked with the dopaminergic projection from the VTA to the ventral striatum, connectivity between the SuM and these regions is either absent or scarce [9-14]. Additional connectivity analysis suggests that several regions that are reciprocally connected with the SuM are also reciprocally connected with the VTA [1]. These include the medial prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus. Moreover, these efferent and afferent regions of the SuM and VTA appear to be closely interlinked. Because these regions have also been implicated in reward-related processes, these brain regions, the mesolimbic dopamine system and SuM may constitute a network module that mediates approach-related motivational processes [1].

Using c-Fos as a marker for neuronal activation, we sought to address the following hypotheses: 1) the administration of GABA_A receptor antagonist picrotoxin into the SuM activates its’ local neurons, because the GABA_A receptor antagonist blocks tonic inhibition, leading to neuronal disinhibition; 2) picrotoxin administration into the SuM activates the mesolimbic dopamine system; 3) picrotoxin administration into the SuM activates the brain regions that are involved in motivational processes and reciprocally connected with both SuM and VTA: medial prefrontal cortex, septum, preoptic area, lateral hypothalamic area, and dorsal raphe nucleus.

In addition, we examined whether intra-SuM administration of picrotoxin facilitates locomotor activity. Positive motivational manipulations such as brain stimulation reward and drugs of abuse are known to acutely facilitate locomotor activity in rats [15,16]. Because our previous studies show positive motivational effects of intra-SuM picrotoxin, we hypothesized that this manipulation will facilitate locomotor activity in open fields. The present study focused on effects of acute intra-SuM picrotoxin administration on locomotor activity and c-Fos expressions in reward-related brain structures. Therefore, the study emphasized on initial unconditioned processes, rather than conditioned processes, triggered by SuM manipulations.

Results and Discussion

Each rat unilaterally received picrotoxin or vehicle into the vicinity of the SuM through a permanent guide cannula. After a locomotor activity test, each rat was killed for histological processes of c-Fos expression and cannula placement. Each rat’s cannula placement was verified with microscopic examination and shown in Figure 1.

Effects of SuM picrotoxin administration on locomotor activity

Unilateral administration of picrotoxin (0.3 mM in 0.3 μl) into the SuM immediately facilitated locomotion and rearing that then gradually decreased over the next 40 min (Figure 2). Because rats that received artificial cerebrospinal fluid into regions just outside the SuM showed similar locomotor/rearing counts as those receiving it into the SuM, the data of both groups were combined together as vehicle control data. During the 60 min observation period, the rats that received picrotoxin into the SuM traveled and reared approximately 4 times more than those that received vehicle. These observations were verified by mixed 3 × 12 (injection manipulation group × 5-min block) ANOVA/MANOVAs. We found significant group × 5 min block interactions, $F_{22,34} = 2.72, P = 0.0042$ for locomotion and $F_{22,34} = 2.31, P = 0.013$ for rearing. These results suggest that picrotoxin injections into the SuM markedly facilitate locomotion and rearing. Because the SuM is closely connected with visceral and affective processing structures rather than motor processing structures and because previous studies suggest positive motivational role of this structure, it is tempting to suggest that locomotor activity triggered by intra-SuM picrotoxin is secondarily facilitated through motivational processes, thereby reflecting unconditioned motivational processes of the manipulation.

Effects of SuM picrotoxin administration on c-Fos in reward related structures

Figures 3, 4, 5 show c-Fos expression from the level of the prefrontal cortex to the level of midbrain raphe nuclei of representative rats. We also quantified c-Fos in selected brain regions (Figure 6) and summarized data in Table 1. Consistent with our hypothesis that picrotoxin administration into the SuM disinhibits its local
neurons, we observed robust c-Fos expression in the SuM after picrotoxin administration into the region (Figures 5A and 7). These findings fit with our previous interpretation that self-administration and conditioned place preference induced by intra-SuM AMPA or picrotoxin are mediated by the excitation of local neurons [3,4].

We observed the pattern of c-Fos expression in the VTA and the ventral striatum paralleled with the connectivity between the VTA and ventral striatum. The posterior but not anterolateral VTA had reliable increases in c-Fos expression after intra-SuM picrotoxin, while the medial nucleus accumbens shell had more reliable increases in c-Fos counts than the accumbens core (Figure 5B; Table 1). These results parallel the projection pattern of dopaminergic neurons from the VTA to the ventral striatum. The posterior VTA has been shown to predominantly project to the medial part of the ventral striatum, including the medial shell, while the anterolateral VTA largely projects to the lateral part of the ventral striatum, including the core [17]. In other words, there is mediolateral topography for dopaminergic neurons projecting from the VTA (posterior-anterolateral) to the ventral striatum (medial-lateral). This congruence between c-Fos and structure suggests that SuM picrotoxin activates the medial part of the mesolimbic dopamine system more reliably than the lateral part, and that the SuM is functionally linked with the medial mesolimbic dopamine system more closely than its lateral counterpart. Because the medial mesolimbic dopamine system appears to mediate drugs’ motivational effects more readily than the lateral portion of the system [17,18], these findings are consistent with our hypothesis that the mesolimbic dopamine system and the SuM interact for approach-related motivational processes.

In addition to the medial mesolimbic dopamine system, we observed increased expression of c-Fos in other regions that are closely connected with both the SuM and VTA. Picrotoxin administration into the SuM increased c-Fos expression in the septal complex, especially the intermediate and ventral parts of the lateral septal nucleus, the medial prefrontal cortex, the lateral preoptic area, the lateral hypothalamic area and the dorsal raphe nucleus. These regions, which are closely connected with both the SuM and VTA and expressed picrotoxin-induced c-Fos, have been previously implicated in positive motivational processes. Rats learn to self-stimulate these regions with brief electrical current [2,19-21]. Injections of drugs into these regions are
rewarding, including cocaine [22] and NMDA receptor antagonists [23] in the medial prefrontal cortex, morphine and muscimol in the septal area [24-26], morphine in the lateral hypothalamic area [27,28], and the GABA<sub>A</sub> receptor agonist muscimol and GABA<sub>B</sub> receptor agonist baclofen in the dorsal raphe nucleus [29,30]. Picrotoxin administration into the SuM tended to increase, without a statistical significance, c-Fos in the medial preoptic nucleus, which is implicated in drug reward [31,32]. The same manipulation significantly increased c-Fos expression in the lateral preoptic nucleus, which supports self-stimulation [33], but has not previously been implicated in drug reward. Because the preoptic nuclei are closely connected with the SuM, VTA and the above-mentioned regions that showed significant c-Fos expression, these nuclei could play an important role in motivational processes initiated through the SuM. Thus, these findings generally support our hypothesis that these brain structures participate in motivational processes mediated through the SuM.

**c-Fos expression following brain stimulation reward**

We mentioned in the background section that carbachol administration into the posterior VTA increases c-Fos expression in the SuM. Similarly, increased c-Fos expression has been found in the SuM and other brain structures that we reported here following rewarding electrical stimulation delivered at the lateral hypothalamic area [34] as well as vicinity of the dorsal raphe nucleus [35]. These previous and present findings are consistent, though not unequivocally, with the view that the SuM is a component of a network module mediating approach-type motivational processes [1].

**Limitations**

To avoid interpreting the results beyond what they are, it is important to acknowledge limitations of our c-Fos technique. c-Fos expression is a correlate of manipulations and thus does not indicate any causal relationship. Accordingly, the technique cannot discriminate between reward-related neurons and other activated neurons. Thus, c-Fos expression does not necessarily mean involvement in positive motivational processes. Furthermore, c-Fos may not necessarily be expressed in every activated cell. Thus, the absence of c-Fos does not indicate the absence of neuronal activation. Finally, the technique does not show how neurons were activated. In particular, our observations suggest that c-Fos expression can result from first-, second- or even third-order trans-synaptic activation. Ipsilateral sides of regions that receive monosynaptic efferents from picrotoxin-affected part of the SuM tended to have more c-Fos expression than the contralateral sides of bilateral structures, including the medial prefrontal cortex, lateral septal area, diagonal band of Broca, preoptic areas and lateral hypothalamic area (Table 1). However, c-Fos expression was generally observed bilaterally throughout the brain.
Figure 3 c-Fos expression in forebrain sections of representative rats after injections of picrotoxin or vehicle into the SuM. Each red dot indicates a nucleus containing c-Fos. Abbreviations: AcbC, nucleus accumbens core; AcbSh, nucleus accumbens shell, medial part; BST, bed nucleus of stria terminalis; Cg, cingulate cortex; LSD, lateral septal nucleus, dorsal part; LSI, lateral septal nucleus, intermediate part; LSV, lateral septal nucleus, ventral part; MS, medial septal nucleus; Pir, piriform cortex; PrL, prelimbic cortex; Tu, olfactory tubercle; VDB, nucleus of the vertical limb of the diagonal band.
Figure 4 c-Fos expression at the level of hypothalamus of representative rats after injections of picrotoxin or vehicle into the SuM

Abbreviations: BLA, basolateral amygdaloid nucleus; Ce, central amygdaloid nucleus; CM, central medial thalamic nucleus; DG, dentate gyrus of hippocampus; LPO, lateral preoptic nucleus; MPA, medial preoptic nucleus; Pa paraventricular hypothalamic nucleus; PLH, peduncular part of lateral hypothalamus; Pir, piriform cortex; PT, paratenial thalamic nucleus; PV, paraventricular thalamic nucleus; Re, reuniens thalamic nucleus; RSGc, rostrosplenial granular cortex, c region.
Figure 5 c-Fos expression in brainstem sections of representative rats after injections of picrotoxin or vehicle into the SuM

Abbreviations: DR, dorsal raphe nucleus; IC, inferior colliculus; IP, interpeduncular nucleus; MnR, median raphe nucleus; PAG, periaqueductal gray; Pn, pontine nuclei; SC, superior colliculus; SuM, supramammillary nucleus; VTAp, posterior ventral tegmental area; VTg, ventral tegmental nucleus of Gudden.
including regions that do not receive efferents from the SuM (Figures 3, 4 and 5).

**Conclusion**

Administration of the GABA<sub>A</sub> receptor antagonist picrotoxin into the SuM, which was previously found to recruit positive motivational processes related to approach/seeking, facilitated locomotor activity and induced c-Fos expression in extensive brain structures. The patterns of c-Fos expression suggest that it disinhibits local neurons and recruits activation of the mesolimbic dopamine system, prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus. These brain structures may be involved
Table 1 c-Fos counts in reward-related regions following an injection of either vehicle or picrotoxin into the SuM or its vicinity

| Region                               | Distance (mm) | Hemi-sphere | PIC-SUM (N = 14) | PIC-OUT (N = 7) | VEH (N = 9) | P-value | P-value | P-value | Mean |
|--------------------------------------|---------------|-------------|------------------|-----------------|-------------|---------|---------|---------|------|
| Cortex                               |               |             |                  |                 |             |         |         |         |      |
| Medial prefrontal cortex             | 2.8           | i           | 71.4             | 0.0042          | 40.7        | 0.2695  | 26.3    |         |      |
|                                      | 2.8           | c           | 60.2             | 0.0399          | 30.6        | 0.8129  | 27.7    |         |      |
| Retrosplenial granular cortex        | -2.8          | i           | 50.2             | 0.0572          | 45.4        | 0.0402  | 5.7     |         |      |
|                                      | -2.8          | c           | 35.8             | 0.327           | 32.7        | 8.4     |         |         |      |
| Hippocampus dentate gyrus           | -2.8          | i           | 44.1             | 14.4            | 4.6         |         |         |         |      |
|                                      | -2.8          | c           | 41.3             | 7.9             | 1.9         |         |         |         |      |
| Basolateral nucleus of amygdala     | -2.8          | i           | 11.8             | 18.3            | 3.3         |         |         |         |      |
|                                      | -2.8          | c           | 12.9             | 17.3            | 4.6         |         |         |         |      |
| Basal forebrain                     |               |             |                  |                 |             |         |         |         |      |
| Central nucleus of amygdala         | -2.8          | i           | 6.6              | 33.1            | 8.2         |         |         |         |      |
|                                      | -2.8          | c           | 6.9              | 7.0             | 6.2         |         |         |         |      |
| Lateral septal nucleus, dorsal part | 2.0           | i           | 43.7             | 56.3            | 0.0263      | 11.4    |         |         |      |
|                                      | 2.0           | c           | 38.7             | 41.1            | 1.22        |         |         |         |      |
|                                      | 1.0           | i           | 13.0             | 24.1            | 1.6         |         |         |         |      |
|                                      | 1.0           | c           | 10.3             | 22.3            | 1.6         |         |         |         |      |
|                                      | 0.0           | i           | 18.4             | 6.4             | 0.4434      | 1.8     |         |         |      |
|                                      | 0.0           | c           | 17.4             | 10.6            | 0.1427      | 1.3     |         |         |      |
| Lateral septal nucleus, intermediate part | 2.0      | i           | 72.9             | 16.6            | 0.0507      | 5.8     |         |         |      |
|                                      | 2.0           | c           | 43.9             | 13.4            | 0.5993      | 8.7     |         |         |      |
|                                      | 1.0           | i           | 194.1            | 74.4            | 0.1148      | 7.7     |         |         |      |
|                                      | 1.0           | c           | 99.9             | 35.4            | 0.3642      | 1.24    |         |         |      |
|                                      | 0.0           | i           | 57.1             | 26.1            | 0.1900      | 4.3     |         |         |      |
|                                      | 0.0           | c           | 45.3             | 17.0            | 0.3078      | 3.7     |         |         |      |
| Lateral septal nucleus, ventral part | 2.0          | i           | 150.1            | 76.9            | 0.0730      | 18.0    |         |         |      |
|                                      | 2.0           | c           | 86.3             | 57.0            | 0.0887      | 22.2    |         |         |      |
|                                      | 1.0           | i           | 297.4            | 102.9           | 0.1989      | 32.3    |         |         |      |
|                                      | 1.0           | c           | 158.1            | 52.6            | 0.6105      | 36.6    |         |         |      |
|                                      | 0.0           | i           | 139.6            | 96.9            | 0.0205      | 8.6     |         |         |      |
|                                      | 0.0           | c           | 81.1             | 61.4            | 0.0202      | 6.9     |         |         |      |
| Septohypothalamic nucleus           | 0.0           | i           | 127.1            | 55.6            | 0.1279      | 12.0    |         |         |      |
|                                      | 0.0           | c           | 73.0             | 54.9            | 0.0423      | 1.17    |         |         |      |
| Medial septal nucleus               | 1.0           | i           | 172              | 10.4            | 6.4         |         |         |         |      |
|                                      | 0.0           | c           | 18.9             | 14.7            | 0.0290      | 1.7     |         |         |      |
| Nucleus of the vertical limb of the diagonal band | 1.0   | i           | 21.9             | 10.0            | 0.2844      | 1.6     |         |         |      |
|                                      | 1.0           | c           | 6.2              | 10.1            | 1.1         |         |         |         |      |
| Nucleus of the horizontal limb of the diagonal band | 1.0 | i           | 19.0             | 11.6            | 0.0778      | 1.6     |         |         |      |
|                                      | 1.0           | c           | 4.3              | 6.1             | 1.7         |         |         |         |      |
| Nucleus accumbens core              | 2.0           | i           | 31.4             | 46.4            | 2.9         |         |         |         |      |
|                                      | 2.0           | c           | 25.9             | 2.0             | 0.8836      | 3.6     |         |         |      |
|                                      | 1.0           | i           | 12.6             | 3.4             | 2.1         |         |         |         |      |
|                                      | 1.0           | c           | 9.6              | 3.4             | 2.8         |         |         |         |      |
| Nucleus accumbens shell, medial part | 2.0          | i           | 48.2             | 7.1             | 0.8499      | 5.1     |         |         |      |
|                                      | 2.0           | c           | 43.8             | 10.6            | 0.6573      | 6.1     |         |         |      |
|                                      | 1.0           | i           | 23.4             | 12.9            | 0.1577      | 2.4     |         |         |      |
in approach-type motivational processes triggered by activation of supramammillary neurons.

**Methods**

**Animals**

Thirty male Wistar rats (Harlan, Dublin, VA, USA) weighing 250-350 g at the time of surgery were used in this experiment. They were initially housed in pairs, and after surgery, were housed individually in a humidity controlled room kept at a constant temperature and on a reverse 12-h light-dark cycle (lights on at 9:00 PM). Food and water were freely available except during testing. All procedures were approved by the Animal Care and Use Committee of the National Institute on Drug Abuse Intramural Research Program and were in accordance with the National Institutes of Health guidelines.

**Surgery**

Under sodium pentobarbital (31 mg/kg, i.p.) and chloral hydrate (142 mg/kg, i.p.) anesthesia, rats were implanted unilaterally with a single guide cannula (24 gauge, Plastics One, VA, USA) into the left hemisphere that ended 1.0 mm rostral and dorsal to the supramammillary nucleus. While the injection cannula, which extended 1.0 mm beyond the tip of the guide, was not in use, a 28 gauge dummy stylet maintained the patency of the guide cannula, which extended 0.5 mm beyond the tip of the guide. Using a digital stereotaxic instrument, the following target coordinates (in millimeters) were measured: 3.8 - 4.3 posterior to bregma, 0.5 lateral to the midline, and 8.4 ventral to the skull surface. The cannulae were inserted at a 30° on the rostrocaudal plain from a rostral-to-caudal direction and a 7° on the mediolateral plain from a

| Reward-related regions | Vehicle (c-Fos) | Picrotoxin (c-Fos) | Vehicle (p-value) | Picrotoxin (p-value) |
|------------------------|----------------|------------------|------------------|------------------|
| Olfactory tubercle     | 1.0 c 18.6    | 0.0361 8.4       | 0.3962 3.4       |
| Paraventricular thalamic nucleus | -1.0 i 50.2     | 0.0494 24.0       | 0.4813 14.7       |
| Central medial thalamic nucleus | -2.0 m 43.6     | 0.0053 21.6       | 0.2622 9.1       |
| Lateral habenula       | -3.0 i 18.7    | 0.0001 2.4       |
| Medial preoptic area   | 0.0 i 34.1     | 0.0313 50.3      | 0.0422 7.3       |
| Lateral preoptic area  | 0.0 c 18.6     | 0.0001 2.4       |
| Dorsomedial hypothalamic nucleus | -1.0 i 35.3  | 0.0018 39.9      | 0.0120 2.2       |
| Lateral hypothalamic area | -2.0 i 30.1  | 0.0021 22.0      | 0.0444 4.9       |
| Supramamillary n       | -4.0 m 187.0   | 0.0001 48.3       |
| Anterolateral VTA      | -5.0 i 23.1    | 0.0001 4.9       |
| Posterior VTA          | -5.8 i 9.6     | 0.0015 4.1       | 0.2728 1.0       |
| Central linear n       | -6.7 m 39.7    | 0.0001 4.9       |
| Dorsal raphe n         | -7.8 m 21.1    | 0.0025 16.0      | 0.0498 1.7       |
| Median raphe n         | -7.8 m 15.4    | 0.0001 4.9       |

Notes: c-Fos counts in bold indicate significant differences from respective counts for vehicle injections. Blank space in the p-value columns indicates that the effect of region was not significant, following an ANOVA/MANOVA test. Abbreviations: c, contralateral to injection site; i, ipsilateral to injection site; m, midline; n, nucleus.
periphery-to-midline direction. This angular positioning of the cannulae was used to minimize tissue destruction when brains were cut for coronal sections, particularly at the level of injection site. If cannulae had been placed vertically from the dorsal entry just above the injection site, coronal sections at the level of the injection site would have been easily damaged due to the cannula track, which would have hindered c-Fos counts and our ability to locate the injection site. All depth measurements were made from the skull surface with the incisor bar set at 3.3 mm below the interaural line. The cannulae were subsequently anchored to the skull with 4 screws and dental acrylic. Animals were allowed 3 postsurgical recovery days, before we started daily handling for 2 minutes over 3 consecutive days in experimental room.

Figure 7 Photomicrographs showing representative injection sites in coronal sections at the level of the supramammillary nucleus. Arrows indicate the tips of injection cannulae for injections of picrotoxin (A) and vehicle (B). Abbreviations: fr, fascicular retroflexus; ml, medial lemniscus; pm, principal mammillary tract.
Drugs
The GABA<sub>A</sub> antagonist, picrotoxin (Sigma, St. Louis, MO) was dissolved in artificial cerebrospinal fluid consisting of (in mM): 148 NaCl, 2.7 KCl, 1.2 CaCl<sub>2</sub>, and 0.85 MgCl<sub>2</sub>, pH adjusted to 6.5-7.8.

Drug administration and behavioral monitoring
Each rat was individually placed in a Plexiglas locomotor chamber (40 x 40 x 30 cm; AccuScan Instrument, Columbus, OH) equipped with infrared detectors to record horizontal distance traveled and frequency of vertical movements (a measure of rearing incidents) for 2 hours per day for 7 consecutive days. On days 1-5, after 60 min in the locomotor chamber, each rat was allowed to become accustomed to handling procedures for microinjection without actual injections. The rat was placed in a cylinder (30 cm in diameter) for 2 min and returned to the locomotor chamber. On day 6, after the first 60 min in the locomotor chamber, each rat was placed in the cylinder, and its dummy stylet was removed and replaced with an injection cannula (31 gauge) attached to polyethylene tubing via a 10 μl Hamilton gas tight syringe controlled by a Harvard pump (model 22). The rat received vehicle (300 nl) over 60 sec, followed by additional 30 sec before the injection cannula was removed. Immediately after the dummy stylet was placed, the rat was returned to the locomotor chamber for additional 60 min. On day 7, rats received either 0.3 mM picrotoxin or vehicle with the procedure described above.

Histology
Ninety minutes following microinjections of picrotoxin or vehicle, rats were given sodium pentobarbital (31 mg/kg, i.p.) and chloral hydrate (142 mg/kg, i.p.) anesthesia and perfused intracardially with 0.9% saline with 0.2% sodium nitrite solution followed by a 4% paraformaldehyde solution. Their brains were then removed and placed in 4% paraformaldehyde solution for 48 hours. After being transferred to a mixture of 18% sucrose and 2% sodium nitrite solution followed by a 4% paraformaldehyde solution. Their brains were then removed and placed in 4% paraformaldehyde solution for 4 hours before being transferred to a mixture of 18% sucrose and 2% paraformaldehyde fixative for another 2 days prior to sectioning. Using a cryostat, frozen coronal sections, taken at 40 μm from the level of the prefrontal cortex to the level of the caudal pontine reticular nucleus, were submerged in phosphate buffered saline (PBS) and subsequently processed for c-Fos immunoreactivity described below. One of five consecutive sections was taken for processing. Boundaries of the SuM and other brain regions as defined by the atlas of the Paxinos and Watson [36] were determined on the basis of cytoarchitectonic features of each section. If a cannula’s 0.3 mm tip was not found within the SuM, it was considered outside this structure.

Immunohistochemical procedure
After washing in PBS, sections were incubated in 0.3% hydrogen peroxide for 10 min followed by 3 x 10 min rinses with PBS. Sections were subsequently treated with normal goat serum (Vector Laboratories, Burlingame, CA) with 0.25% Triton X-100 in PBS for 2 h. They were then incubated overnight at 4°C with anti-c-Fos rabbit antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) diluted in PBS containing 0.25% Triton X-100. After rinsing 4 x 15 min in PBS, sections were incubated in a 1:200 dilution of the biotinylated secondary antibody for 2 h. After 3 x 10 min rinses with PBS, samples were treated with avidin-biotinylated enzyme complex (Vector Laboratories) for 1 h. Samples were then rinsed with PBS for 2 x 10 min and subjected to a 0.05% 3,3-diaminobenzidine-4 HCl (DAB) and 0.003% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) solution followed by final 3 x 10 min rinses with PBS. Sections were subsequently mounted on gelatin coated slides and air-dried overnight. All sections were then incubated with Methyl Green (Vector Laboratories) for 10 min for counterstaining.

Quantification and visualization of c-Fos
c-Fos was quantified under light microscopic examination with a 20× objective using imaging software (NIS Elements, v2.1, Nikon Instruments, Melville, NY). The sampling area was 325 x 425 μm with a 300 minimum and 3000 maximum detection threshold. We chose brain regions (Figure 6) that have been implicated in drug reward or are major projection targets of the supramammillary nucleus. c-Fos counts were recorded from brain regions of both hemispheres. In addition, we examined coronal sections of two representative brains receiving picrotoxin and vehicle for c-Fos expression throughout the brain, using a Nikon 80i light microscope equipped with a 20× objective and motorized-stage controlled by Neurolucida (MBF Bioscience, Williston, VT).

Statistical Analyses
Data were analyzed with the ANOVA/MANOVA module of Statistica (version 6.1, StatSoft, Inc., Tulsa, OK). When the sphericity assumption examined by Mauchley Sphericity Test was violated for repeated factors, effects of the repeated factors were analyzed by MANOVAs; otherwise ANOVAs were used. When factors with more than two levels were found to be significant, we performed Newman-Keuls posthoc tests. Pearson’s product-moment correlation coefficients were calculated between c-Fos counts and locomotion or rearing scores (during the first 30 min) among all the rats including rats received picrotoxin outside of the SuM and vehicle (N = 30).
Shin and Ikemoto BMC Neuroscience 2010, 11:101
http://www.biomedcentral.com/1471-2202/11/101

List of Abbreviations
PBS: phosphate buffer solution; SuM: supramammillary nucleus; VTA: ventral tegmental area.

Authors’ contributions
Sl conceived the study; RS and SI designed experiments; RS conducted experiments and measured c-Fos expression; RS and SI analyzed data and wrote the paper. Both authors read and approved the final manuscript.

Acknowledgements
This research was supported by the Intramural Research Program of National Institute on Drug Abuse, National Institutes of Health (Z01-DA000439).

Received: 9 December 2009 Accepted: 17 August 2010 Published: 17 August 2010

References
1. Ikemoto S: Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neuroscience & Biobehavioral Reviews 2010.
2. Olds ME, Olds J: Approach-avoidance analysis of rat diencephalon. J Comp Neurol 1963, 120:259-295.
3. Ikemoto S: The supramammillary nucleus mediates primary reinforcement via GABA(A) receptors. Neuropeychopharmacology 2005, 30(1088-1095).
4. Ikemoto S, Witkin BM, Zangen A, Wise RA: Rewarding effects of AMPA administration into the supramammillary or posterior hypothalamic nuclei but not the ventral tegmental area. J Neurosci 2004, 24(25):5758-5765.
5. Ikemoto S, Qin M, Liu ZH: Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area. J Neurosci 2006, 26(3):723-730.
6. Ikemoto S, Wise RA: Rewarding effects of the cholinergic agents carbachol and neostigmine in the posterior ventral tegmental area. J Neurosci 2002, 22:9895-9904.
7. Westenink BH, Kwint HF, delVries JB: The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 1996, 16(8):2605-2611.
8. Ikemoto S, Witkin BM, Morales M: Rewarding injections of the cholinergic antagonist carbachol into the ventral tegmental area induce locomotion and c-Fos expression in the retrosplenial area and supramammillary nucleus. Brain Res 2003, 969:78-87.
9. Vertes RP: PHAL analysis of projections from the supramammillary nucleus in the rat. J Comp Neurol 1992, 326(4):595-622.
10. Vertes RP, McKenna JT: Collateral projections from the supramammillary nucleus to the medial septum and hippocampus. Synapse 2000, 38(3):281-293.
11. Gonzalez-Ruiz A, Mota L, Flecha JM, Sanz JM: Neurotransmitter characteristics of neurons projecting to the supramammillary nucleus of the rat. Anat Embryol (Berl) 1999, 200(4):377-392.
12. Hayakawa T, Ito H, Zyo K: Neuroanatomical study of afferent projections to the supramammillary nucleus of the rat. Anat Embryol (Berl) 1993, 188(2):139-148.
13. Geisler S, Wise RA: Efferent projections of the rostral and caudal ventral tegmental area in rat. Society for Neuroscience Abstract 2007.
14. Geisler S, Zahm DS: Afferents of the ventral tegmental area in the rat-anatomical substratum for integrative functions. J Comp Neurol 2005, 490(3):270-294.
15. Panksepp J: Hypothalamic integration of behavior: Rewards, punishments, and related psychological processes. Handbook of hypothalasmus. Vol 2 Behavioral studies of the hypothalamus New York: Marcel DekkerMorgane, PJ; Panksepp J 1981, 289-431.
16. Wise RA, Bozarth MA: A psychomotor stimulant theory of addiction. Psychol Rev 1987, 94:469-492.
17. Ikemoto S: Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens-offactory tubercle complex. Brain Research Reviews 2007, 56(1):275-278.
18. Ikemoto S, Wise RA: Mapping of chemical trigger zones for reward. Neuropharmacology 2004, 47(Suppl 1):190-201.
19. Waraczynski MA: The central extended amygdala network as a proposed circuit underlying reward valuation. Neurosci Biobehav Rev 2006, 30(4):472-496.
20. Routtenberg A, Sloan M: Self-stimulation in the frontal cortex of rattus norvegicus. Behav Biol 1972, 7:505-572.
21. Rompré PP, Millares E: Pontine and mesencephalic substrates of self-stimulation. Brain Res 1985, 359:246-259.
22. Goeders NE, Smith JE: Cortical dopaminergic involvement in cocaine reinforcement. Science 1985, 221:773-775.
23. Carlezon WA Jr, Wise RA: Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 1996, 16:3112-3122.
24. Le Meur J, Gavello-Baudy S, Galey D, Cazaia P: Morphine self-administration into the lateral septum depends on dopaminergic mechanisms: Evidence from pharmacology and Fos neuroimaging. Behav Brain Res 2007, 180(2):203-217.
25. Cazaia P, Norenia A, Le Meur J, Galey D: Differential involvement of the lateral and medial divisions of the septal area on spatial learning processes as revealed by intracranial self-administration of morphine in mice. Behav Brain Res 1998, 97:179-188.
26. Gavello-Baudy S, Le Meur J, Decorte I, David V, Cazaia P: Self-administration of the GABA(A) agonist muscimol into the medial septum: dependence on dopaminergic mechanisms. Psychopharmacology 2008, 201(2):219-228.
27. Olds ME: Hypothalamic substrate for the positive reinforcing properties of morphine in the rat. Brain Res 1979, 168:351-360.
28. Cazaia P, David V: Dose-discrimination performance of mice for self-administration of morphine into the lateral hypothalamus. Pharmacol Biochem Behav 1995, 51(1):49-55.
29. Liu ZH, Ikemoto S: The midbrain raphe nucleus mediates primary reinforcement via GABA(A) receptors. Eur J Neurosci 2007, 25(3):735-743.
30. Shin R, Ikemoto S: The GABA(A) receptor agonist baclofen administered into the median and dorsal raphe nucleus is rewarding as shown by intracranial self-administration and conditioned place preference in rats. Psychopharmacology 2010, 208:545-554.
31. Agmo A, Gomez M: Conditioned place preference produced by infusion of Met-enkephalin into the medial preoptic area. Brain research 1991, 550(2):343-346.
32. King BE, Packard MG, Alexander GM: Affective properties of intramedial preoptic area injections of testosterone in male rats. Neuroscience Letters 1999, 269(3):149-152.
33. Bushnik T, Belajew C, Konkle ATM: The substrate for brain-stimulation reward in the lateral preoptic area: I. Anatomical mapping of its boundaries. Brain research 2000, 881(2):103-111.
34. Arvanitogiannis A, Flores C, Shizgal P: Fos-like immunoreactivity in the caudal diencephalon and brainstem following lateral hypothalamic self-stimulation. Behav Brain Res 1997, 88(2):275-279.
35. Marangione C, Rompré PP: Topographical Fos induction within the ventral midbrain and projection sites following self-stimulation of the posterior mesencephalon. Neuroscience 2008, 154(4):1227-1241.
36. Paxinos G, Watson C: The rat brain in stereotactic coordinates Burlington, MA: Elsevier, S 2005.

doi:10.1186/1471-2202-11-101
Cite this article as: Shin and Ikemoto: Administration of the GABA(A) receptor antagonist picrotoxin into rat supramammillary nucleus induces c-Fos in reward-related brain structures. Supramammillary picrotoxin and c-Fos expression. BMC Neuroscience 2010 11:101.